Juliana Setyawan

Economic Impact of Childhood and Adult Attention-Deficit/Hyperactivity Disorder in the United States

OBJECTIVE Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent mental disorders in children in the United States and often persists into adulthood with associated symptomatology and impairments. This article comprehensively reviews studies reporting ADHD-related incremental (excess) costs for children/adolescents and adults and presents estimates of annual national incremental costs of ADHD. METHOD A systematic search for primary United States-based studies published from January 1, 1990 through June 30, 2011 on costs of children/adolescents and adults with ADHD and their family members was conducted. Only studies in which mean annual incremental costs per individual with ADHD above non-ADHD controls were reported or could be derived were included. Per-person incremental costs were adjusted to 2010 U.S. dollars and converted to annual national incremental costs of ADHD based on 2010 U.S. Census population estimates, ADHD prevalence rates, number of household members, and employment rates by age group. RESULTS Nineteen studies met the inclusion criteria. Overall national annual incremental costs of ADHD ranged from

Adult ADHD patient experiences of impairment, service provision and clinical management in England: a qualitative study

143 to

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil

266 billion (B). Most of these costs were incurred by adults (

Cost Effectiveness of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder

105 B-

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine

194 B) compared with children/adolescents (

Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.

38 B-

A new measure of caregiver burden in Alzheimer's disease: the caregiver-perceived burden questionnaire.

72 B). For adults, the largest cost category was productivity and income losses (

Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications

87 B-

Variation in Presentation, Diagnosis, and Management of Children and Adolescents With ADHD Across European Countries.

138 B). For children, the largest cost categories were health care (

Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults

21 B-